Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion Healthcare Co., Ltd.
  6. Summary
    A091990   KR7091990002

CELLTRION HEALTHCARE CO., LTD.

(A091990)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Korea Stock Exchange
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
87400 89600 89600 88300 88000 Last
521364 578888 452986 393845 687525 Volume
+0.46% +2.52% 0.00% -1.45% -0.34% Change
Estimated financial data (e)
Sales 2021 1 881 B 1,60 B 1,60 B
Net income 2021 258 B 0,22 B 0,22 B
Net cash position 2021 225 B 0,19 B 0,19 B
P/E ratio 2021 52,7x
Yield 2021 -
Sales 2022 2 372 B 2,02 B 2,02 B
Net income 2022 405 B 0,35 B 0,35 B
Net cash position 2022 676 B 0,58 B 0,58 B
P/E ratio 2022 34,0x
Yield 2022 -
Capitalization 13 489 B 11 473 M 11 479 M
EV / Sales 2021 7,05x
EV / Sales 2022 5,40x
Nbr of Employees 131
Free-Float 60,7%
More Financials
Company
Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn’s disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of... 
Sector
Pharmaceuticals
Calendar
11/18Earnings Release
More about the company
Ratings of Celltrion Healthcare Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about CELLTRION HEALTHCARE CO., LTD.
10/03Celltrion Healthcare Showcases Positive Data on Switching and Monotherapy with Remsima®..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/18Celltrion Receives Approval from Korean Ministry of Food and Drug Safety for regdanvima..
CI
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/02Celltrion Healthcare Canada Limited Announces Acceptance and Priority Review by Health ..
CI
07/16Celltrion’S Monoclonal Antibody Treatment for COVID-19, Regdanvimab, Demonstrates Stron..
CI
06/29EU picks antibody treatments, arthritis drug as preferred COVID-19 therapies
RE
06/14Celltrion Healthcare Announces Positive Top-Line Results from Global Phase III Trial of..
CI
06/12Celltrion Healthcare Presents the First Real-World Data for Truxima®
CI
06/01Celltrion Healthcare Presents Positive One-Year Data for YuflymaTM (Ct-P17)
CI
05/18Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-..
CI
04/29Celltrion Group Announces Preliminary Pre-Clinical Results for Regdanvimab
CI
03/31Celltrion Healthcare Receives Positive Chmp Opinion for Subcutaneous Formulation of Inf..
CI
02/16Celltrion Healthcare Receives European Commission Approval for the First High Concentra..
CI
More news
News in other languages on CELLTRION HEALTHCARE CO., LTD.
10/04COVID : Ema valuta autorizzazione immissione in commercio Regkirona
09/20180 Life Sciences prévoit un accord de fourniture avec Celltrion Healthcare pour les es..
More news
Chart CELLTRION HEALTHCARE CO., LTD.
Duration : Period :
Celltrion Healthcare Co., Ltd. Technical Analysis Chart | A091990 | KR7091990002 | MarketScreener
Technical analysis trends CELLTRION HEALTHCARE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 88 000,00 KRW
Average target price 124 600,00 KRW
Spread / Average Target 41,6%
EPS Revisions
Managers and Directors
Hyung-Ki Kim Chief Executive Officer & Director
Jung-Jin Seo Chairman
Jung Kim Head-Compliance Support
David Han Independent Director
Eung-Yeol Choe Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CELLTRION HEALTHCARE CO., LTD.-46.01%11 418
CSL LIMITED4.59%99 388
WUXI BIOLOGICS (CAYMAN) INC.14.69%62 669
SAMSUNG BIOLOGICS CO.,LTD.5.08%47 893
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.10.16%40 199